A detailed history of Two Sigma Investments, LP transactions in Sana Biotechnology, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 146,256 shares of SANA stock, worth $241,322. This represents 0.0% of its overall portfolio holdings.

Number of Shares
146,256
Previous 413,510 64.63%
Holding current value
$241,322
Previous $2.26 Million 73.06%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.76 - $6.86 $1 Million - $1.83 Million
-267,254 Reduced 64.63%
146,256 $608,000
Q2 2024

Aug 14, 2024

BUY
$5.23 - $10.44 $1.69 Million - $3.38 Million
323,710 Added 360.48%
413,510 $2.26 Million
Q1 2024

May 15, 2024

BUY
$4.2 - $11.27 $63,176 - $169,523
15,042 Added 20.12%
89,800 $898,000
Q4 2023

Feb 14, 2024

SELL
$2.8 - $4.55 $133,750 - $217,344
-47,768 Reduced 38.99%
74,758 $305,000
Q3 2023

Nov 14, 2023

SELL
$3.77 - $6.23 $531,309 - $878,000
-140,931 Reduced 53.49%
122,526 $474,000
Q2 2023

Aug 14, 2023

BUY
$3.22 - $7.53 $553,701 - $1.29 Million
171,957 Added 187.93%
263,457 $1.57 Million
Q1 2023

May 15, 2023

BUY
$3.11 - $4.92 $155,954 - $246,718
50,146 Added 121.26%
91,500 $299,000
Q4 2022

Feb 14, 2023

SELL
$3.19 - $6.46 $352,680 - $714,204
-110,558 Reduced 72.78%
41,354 $163,000
Q3 2022

Nov 14, 2022

BUY
$5.58 - $9.04 $525,429 - $851,233
94,163 Added 163.06%
151,912 $911,000
Q2 2022

Aug 15, 2022

SELL
$4.12 - $9.35 $742,827 - $1.69 Million
-180,298 Reduced 75.74%
57,749 $371,000
Q1 2022

May 16, 2022

BUY
$5.24 - $15.58 $832,038 - $2.47 Million
158,786 Added 200.33%
238,047 $1.97 Million
Q4 2021

Feb 14, 2022

BUY
$15.18 - $23.15 $1.2 Million - $1.83 Million
79,261 New
79,261 $1.23 Million

Others Institutions Holding SANA

About Sana Biotechnology, Inc.


  • Ticker SANA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 190,232,000
  • Market Cap $314M
  • Description
  • Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others...
More about SANA
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.